55368-68-8

Upstream product

• 1878-82-6 (4-cyanophenoxy)acetic acid 
• 30041-95-3 ethyl (4-cyano-phenoxy)-acetate 
• 767-00-0 4-cyanophenol 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 1541987-89-6 N-[2-amino-6-[(4-cyanobenzyl)oxy]pyridin-3-yl]-2-(4-cyanophenoxy)acetamide 
• 1541987-92-1 4-[[5-(4-cyanobenzyloxy)-3H-imidazo[4,5-b]pyridin-2-yl]methoxy]benzonitrile 
• 1599524-75-0 methyl 5-bromo-2-(2-(4-cyanophenoxy)acetamido)benzoate 
• 1599524-76-1 4-((6-bromo-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl)oxy)benzonitrile 
• 1599524-77-2 4-((6-bromo-2,4-dichloroquinolin-3-yl)oxy)benzonitrile 
• 1599524-78-3 4-((2-(azetidin-1-yl)-6-bromo-4-chloroquinolin-3-yl)oxy)benzonitrile 
• 1599524-79-4 4-((6-bromo-4-chloro-2-(pyrrolidin-1-yl)quinolin-3-yl)oxy)benzonitrile 
• 1599525-44-6 4-((2-(Azetidin-1-yl)-4-chloro-6-(hydroxy(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)quinolin-3-yl)oxy)benzonitrile 
• 1599525-48-0 4-((2-(Azetidin-1-yl)-4-chloro-6-((4-chlorophenyl)(hydroxyl)(1-methyl-1H-imidazol-5-yl)methyl)quinolin-3-yl)oxy)benzonitrile 
• 1599525-52-6 4-((4-chloro-6-(hydroxy(1-methyl-1H-imidazole-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(pyrrolidin-1-yl)quinolin-3-yl)oxy)benzonitrile 
• 1308209-11-1 2-(4-cyanophenoxy)-N-ethyl-N-(thiophen-2-ylmethyl)acetamide 
• 189329-83-7 C₉H₈N₂O₂ 
• 452349-91-6 methyl 5-bromo-2-(2-(4-chlorophenoxy)acetamido)benzoate 
• 1599524-73-8 6-bromo-2,4-dichloro-3-(4-chlorophenoxy)quinoline 

Relevant academic research and scientific papers

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Discovery and development of a novel class of phenoxyacetyl amides as highly potent TRPM8 agonists for use as cooling agents

The paper presents the activity trends for a novel series of phenoxyacetyl amides as human TRPM8 receptor agonists. This series encompasses in vitro activity values ranging from the micromolar to the picomolar levels. Sensory evaluation of these molecules highlights their relevance as cooling agents for oral applications. The positive outcome of the complete evaluation of N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide resulted in its approval for Generally Recognized As Safe (GRAS) status by the Flavor & Extract Manufacturer Association (FEMA) as FEMA 4809.

HETEROARYL LINKED QUINOLINYL MODULATORS OF RORγT

The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification, The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndro

HETEROARYL LINKED QUINOLINYL MODULATORS OF ROR?T

The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification, The invention also

HETEROARYL LINKED QUINOLINYL MODULATORS OF RORgammat

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7 R8, and R9 are defined in the specification. The invention also

HETEROARYL LINKED QUINOLINYL MODULATORS OF RORGAMMAT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndr

Design and synthesis of heterocyclic cations for specific DNA recognition: From AT-rich to mixed-base-pair DNA sequences

The compounds synthesized in this research were designed with the goal of establishing a new paradigm for mixed-base-pair DNA sequence-specific recognition. The design scheme starts with a cell-permeable heterocyclic cation that binds to AT base pair sites in the DNA minor groove. Modifications were introduced in the original compound to include an H-bond accepting group to specifically recognize the G-NH that projects into the minor groove. Therefore, a series of heterocyclic cations substituted with an azabenzimidazole ring has been designed and synthesized for mixed-base-pair DNA recognition. The most successful compound, 12a, had an azabenzimidazole to recognize G and additional modifications for general minor groove interactions. It binds to the DNA site -AAAGTTT- more strongly than the -AAATTT- site without GC and indicates the design success. Structural modifications of 12a generally weakened binding. The interactions of the new compound with a variety of DNA sequences with and without GC base pairs were evaluated by thermal melting analysis, circular dichroism, fluorescence emission spectroscopy, surface plasmon resonance, and molecular modeling.